Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Cachexia & Metabolic Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GDF15 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GDF15 Recombinant Protein (Dimeric) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed for authentic disulfide bonding. |
View GDF15 Products |
| Receptor | GFRAL Recombinant Protein (ECD-Fc) For binding competition assays. Theoretical MW verified. |
View GFRAL Products |
| Gene Delivery | GDF15 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction, cachexia model development. |
View GDF15 Products |
| Benchmark Ab | Anti-GDF15 (Ponsegromab Sequence) Recombinant positive control, clinically validated target engagement. |
View GDF15 Products |
| Validator | GDF15 siRNA Set For knockdown verification and specificity controls. |
View GDF15 Products |
| Homology Control | GDF11 Protein For TGF-beta superfamily selectivity screening. Sequence Verified. |
View GDF11 Products |
| Co-Receptor | RET Protein (ECD) Co-receptor for GFRAL signaling complex. For ternary complex assays. |
View RET Products |
| Related Target: GLP-1R | GLP-1R Recombinant Protein / Lentivirus Synergistic target for next-generation obesity combinations. |
View GLP1R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse/human eval | Human/Mouse/Cyno GDF15 ortholog proteins available with >95% purity, sequence verified for tox studies |
| TGF-beta superfamily counter screening | GDF11 homolog protein strictly verified by mass spec for off-target liability assessment |
| Receptor-mediated internalization assays | GFRAL-Fc fusion proteins with native glycosylation for pH-dependent binding studies |
| Lack of Controls | Clinical Benchmark Antibodies (Ponsegromab biosimilar) included |
| False Positives | Validated siRNA included for specificity checks |
| Cell-based potency (pERK/Reporter) | GFRAL Lentivirus for stable cell lines preserves receptor conformation on surface |
| GDF15-GFRAL blocking confirmation | High-purity GDF15 & GFRAL ECD proteins enable SPR and competitive ELISA |
| Receptor Complex Formation (GFRAL/RET) | HEK293 Expressed (Native Glycosylation) ECD proteins for structural integrity |
Live GDF15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GDF15 therapeutics is intensifying with a unique dual-market dynamic. Major players are developing long-acting GDF15 agonists for obesity and metabolic disorders, shifting focus toward next-generation weight-loss strategies that spare muscle mass (Novo Nordisk, Eli Lilly, Amgen). Conversely, GDF15 neutralizing antibodies (antagonists) are advancing rapidly for the treatment of cancer cachexia, with first-generation therapies like Ponsegromab (Pfizer) and NGM120 reaching Phase 3. The next wave of R&D is targeting combination strategies (e.g., GDF15 inhibitors with GLP-1 receptor agonists for obesity) and novel GFRAL-targeted bispecifics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-GDF15 mAb (Antagonists) | Pfizer, NGM Bio, Janssen | Cancer Cachexia, Anorexia | High-affinity GFRAL competition (Need dimeric GDF15 with native conformation) |
| Long-acting Agonists (Fc-Fusion) | Novo Nordisk, Eli Lilly, Amgen | Obesity, Type 2 Diabetes | Receptor Binding Assay (Need high-purity GFRAL/RET ECDs) |
| GFRAL Decoy Receptor | Amgen, Novartis | Obesity, Metabolic Disorders | Ternary complex formation (Need GDF15 + GFRAL + RET proteins) |
| Bispecific | Emerging Biotechs | Refractory Cachexia | Dual binding validation (Need cross-reactive Abs vs human/cyno) |
| Fusion Protein | Preclinical | Weight Loss | Stability at high concentration (Need aggregation-free protein stocks) |
| Combination Peptides / Biologics | Johnson & Johnson, Merck | Refractory Obesity | Selectivity Assay (Need Cross-reactive orthologs for in vivo models) |
Genetic Variants & Clinical Correlates
GDF15 harbors several documented missense variants in dbSNP with potential functional implications:
- rs1059519 (UniProt VAR_047646)
- rs1059369 (UniProt VAR_010386)
- rs1058587 (UniProt VAR_047647)
These variants may influence GDF15 stability, receptor affinity, or disease association. Researchers should account for allelic heterogeneity when designing neutralizing antibodies or agonists. Recombinant GDF15 mutant proteins are available for specificity studies.